Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5062)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 27, 2022 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Colosimo S, Tomlinson JW. Bile acids as drivers and biomarkers of hepatocellular carcinoma. World J Hepatol 2022; 14(9): 1730-1738 [PMID: 36185719 DOI: 10.4254/wjh.v14.i9.1730] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i9/1730.htm |
| Number | Citing Articles |
| 1 |
Rachel M. Golonka, Beng San Yeoh, Piu Saha, Amira Gohara, Ramakumar Tummala, Stanislaw Stepkowski, Amit K. Tiwari, Bina Joe, Frank J. Gonzalez, Andrew T. Gewirtz, Matam Vijay-Kumar. Loss of toll-like receptor 5 potentiates spontaneous hepatocarcinogenesis in farnesoid X receptor–deficient mice. Hepatology Communications 2023; 7(6) doi: 10.1097/HC9.0000000000000166
|
| 2 |
Hang Yang, Tingting Yang, Jiaxin Ding, Xue Wang, Xi Chen, Jia Liu, Ting Shu, Ziteng Wu, Lixin Sun, Xin Huang, Zhenzhou Jiang, Luyong Zhang. Taurocholic acid represents an earlier and more sensitive biomarker and promotes cholestatic hepatotoxicity in ANIT‐treated rats. Journal of Applied Toxicology 2024; 44(11): 1742 doi: 10.1002/jat.4669
|
| 3 |
Hongyan Gou, Ruijie Zeng, Harry Cheuk Hay Lau, Jun Yu. Gut microbial metabolites: Shaping future diagnosis and treatment against gastrointestinal cancer. Pharmacological Research 2024; 208: 107373 doi: 10.1016/j.phrs.2024.107373
|
| 4 |
Jayashi Rajapakse, Saroj Khatiwada, Anna Camille Akon, Kin Lam Yu, Sj Shen, Amany Zekry. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions. Gut Microbes 2023; 15(2) doi: 10.1080/19490976.2023.2240031
|
| 5 |
Fang Zeng, Shi He, Ying Sun, Xue Li, Kaiyang Chen, Hongbin Wang, Shuli Man, Fuping Lu. Abnormal enterohepatic circulation of bile acids caused by fructooligosaccharide supplementation along with a high-fat diet. Food & Function 2024; 15(23): 11432 doi: 10.1039/D4FO03353A
|
| 6 |
Minami Yamauchi, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Mio Tsuruoka, Jun Inoue, Atsushi Masamune, Nariyasu Mano. Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma. Metabolites 2024; 14(9): 513 doi: 10.3390/metabo14090513
|
| 7 |
Sijia Dai, Jingfei Zhu, Xuqiong Chen, Liming Zheng, Xiaoping Li, Longgen Liu. Alteration of serum bile acid profiles of HBV-related hepatocellular carcinoma identified by LC–MS/MS. Journal of Cancer Research and Clinical Oncology 2024; 150(3) doi: 10.1007/s00432-024-05686-6
|
| 8 |
Tadashi Takeuchi, Yumiko Nakanishi, Hiroshi Ohno. Microbial Metabolites and Gut Immunology.
Annual Review of Immunology
2024; 42(1): 153 doi: 10.1146/annurev-immunol-090222-102035
|
| 9 |
Annarosa Floreani, Daniela Gabbia, Sara De Martin. Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(4): 2194 doi: 10.3390/ijms25042194
|
| 10 |
Hashem B. El-Serag, Aaron P. Thrift, Hao Duong, Jing Ning, Saira Khaderi, Amit G. Singal, Sumeet K. Asrani, Jorge A. Marrero, Hannah Powell, Kinza Rizwan, Omar Najjar, Christopher I. Amos, Michelle Luster, Abeer Al-Sarraj, Emad Salem, Michael E. Scheurer, Jagpreet Chhatwal, Salma Kaochar, Fasiha Kanwal. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatology Communications 2024; 8(11) doi: 10.1097/HC9.0000000000000545
|